Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Florida Health Daily.
Press releases published on April 11, 2025
Preliminary Results for the Year Ended 31 December 2024
GlobeNewswire
·
April 11, 2025
April 11, 2025 Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company” or, together with its subsidiaries, the “Group”) Preliminary Results for the Year Ended 31 December 2024 Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), an acquisition-focused clinical …
US Radiotherapy Market worth US$2.49 billion by 2030 with 4.6% CAGR | MarketsandMarkets™.
GlobeNewswire
·
April 11, 2025
Delray Beach, FL, April 11, 2025 (GLOBE NEWSWIRE) -- The US Radiotherapy Market is projected to reach US$2.49 billion by 2030 from US$3.25 billion in 2024, at a CAGR of 4.6%. The US radiotherapy market is growing due to ongoing technological innovations …
FibroBiologics to Present at The Cell & Gene Meeting on the Mediterranean
GlobeNewswire
·
April 11, 2025
HOUSTON, April 11, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics”), a clinical-stage biotechnology company with 240+ patents issued and pending for the development of therapeutics and potential cures for chronic diseases …
Conduit Pharmaceuticals Announces Novel Cocrystal Patent Filing For VTAMA® (tapinarof) with Enhanced Therapeutic and Market Extension Prospects
GlobeNewswire
·
April 11, 2025
Conduit Pharmaceuticals files next generation cocrystal patent for VTAMA® (tapinarof) which the Company believes could be a superior asset with both inflammatory and autoimmune prospectives just as the drug approaches 2027 exclusivity expiration, …
Venus Concept Announces $1.5 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
GlobeNewswire
·
April 11, 2025
TORONTO, April 11, 2025 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, today announced that it has entered into definitive agreements for the purchase and sale of 386, …
ImPact Biotech Announces New Data Presentations at AUA 2025 Highlighting Safety and Efficacy of Padeliporfin VTP
GlobeNewswire
·
April 11, 2025
- Company to present updated preliminary results from ENLIGHTED Phase 3 Study in LG UTUC - - Additional podium presentation to provide updates from long-term evaluation of Padeliporfin VTP in intermediate-risk prostate cancer - TEL AVIV, Israel, April 11, …
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
·
April 11, 2025
BRISBANE, Calif., April 11, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies, today announced the granting of inducement awards on April 2, 2025 to 18 new …
Alignment Healthcare to Announce First Quarter 2025 Financial Results and Host Conference Call Thursday, May 1, 2025
GlobeNewswire
·
April 11, 2025
ORANGE, Calif., April 11, 2025 (GLOBE NEWSWIRE) -- Alignment Healthcare, Inc. (NASDAQ: ALHC), will release its first quarter 2025 financial results on Thursday, May 1, 2025, after market close. Following the release, the company will host a conference call …
Crinetics Pharmaceuticals to Report First Quarter 2025 Financial Results on May 8, 2025
GlobeNewswire
·
April 11, 2025
SAN DIEGO, April 11, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that it will report first quarter 2025 financial results on Thursday, May 8, 2025 after the market closes. Company management will host a …
Palvella Therapeutics Announces QTORIN™ Rapamycin 3.9% Anhydrous Gel for the Treatment of Microcystic Lymphatic Malformations Featured in Oral Presentation by Amy Paller, M.S., M.D., Chair of Dermatology at Northwestern University’s Feinberg School of …
GlobeNewswire
·
April 11, 2025
Presentation highlighted the recent expansion of the Phase 3 SELVA trial to include children 3 to 5 years old Presentation reviewed clinically and statistically significant Phase 2 results and the design of the ongoing Phase 3 SELVA trial Top-line results …
Don’t just read the stats, change the future for seniors with your vote
GlobeNewswire
·
April 11, 2025
Toronto, Ontario, April 11, 2025 (GLOBE NEWSWIRE) -- In this federal election, your vote holds the power to change the future for seniors in Canada. Alarming statistics show that 1 in 3 seniors is at risk of social isolation, 1 in 10 experiences elder …
Optima Health to acquire Cognate Health Limited
GlobeNewswire
·
April 11, 2025
The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 as amended by regulation 11 of the Market Abuse (Amendment) (EU Exit) …
Verve Therapeutics Receives U.S. FDA Fast Track Designation for VERVE-102, an In Vivo Base Editing Medicine Targeting PCSK9
GlobeNewswire
·
April 11, 2025
BOSTON, April 11, 2025 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track …
BON Announces Apple Polyphenol Commercial Order Signed
GlobeNewswire
·
April 11, 2025
XI'AN, China, April 11, 2025 (GLOBE NEWSWIRE) -- Bon Natural Life Limited (Nasdaq: BON) ("BON" or the "Company"), a leading bio-ingredient solution provider in the natural, health and personal care industry, announced a groundbreaking 24-month supply …
Vantage Biosciences Doses First Patient in Phase 2 Clinical Study of Oral VX-01 for Non-Proliferative Diabetic Retinopathy
GlobeNewswire
·
April 11, 2025
LONDON, April 11, 2025 (GLOBE NEWSWIRE) -- Vantage Biosciences, a clinical stage biotechnology company advancing innovative therapies for diabetic eye diseases, today announced that the first patient has been successfully dosed in its Phase 2 clinical …
Inbiome Shatters Diagnostic Delays: IVDR-Certified Platform IDs Bacteria in 5 Hours Across EU Hospitals
GlobeNewswire
·
April 11, 2025
www.inbiome.com Inbiome Shatters Diagnostic Delays: IVDR-Certified Platform IDs Bacteria in 5 Hours Across EU Hospitals Hours, Not Days: EU Approval Accelerates 5-Hour Pathogen ID for Critical Cases Molecular Fingerprinting: AI-Powered ‘DNA Barcode’ Spots …
Basel Medical Group Signs Agreement to Acquire Bethesda Medical to Strengthen Healthcare Ecosystem in Singapore and Southeast Asia
GlobeNewswire
·
April 11, 2025
Singapore, April 11, 2025 (GLOBE NEWSWIRE) -- Basel Medical Group Ltd (Nasdaq: BMGL), today announced the signing of a definitive agreement by its subsidiary Basel Medical Group Pte. Ltd. to acquire Bethesda Medical Pte. Ltd., a leading Singapore-based …